Erlotinib-d6 (hydrochloride) – 1 mg

Brand:
Cayman
CAS:
1189953-78-3
Storage:
-20
UN-No:
Non-Hazardous - /

Erlotinib-d6 (hydrochloride) contains six deuterium atoms located on the methoxy group. It is intended for use as an internal standard for the quantification of erlotinib (Item No. 10483) by GC- or LC-MS. Erlotinib is a tyrosine kinase inhibitor that acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-associated kinase activity (IC50 = 2.5 µM).{18353,18362} This inhibits tumor growth in human head and neck carcinoma (HN5) tumor xenografts in mice with an ED50 value of 9 mg/kg.{18353} Erlotinib also suppresses cyclin-dependent kinase 2 (Cdk2) activity in breast cancer cells (IC50 = 4.6 µM) and JAK2 mutant JAK2V617F (IC50 = 5 µM), which is associated with polycythemia vera, idiopathic myelofibrosis, and essential thrombocythemia.{16061,18355} Formulations containing erlotinib are used to treat certain forms of cancer, including non-small cell lung cancer.{18351,17857}  

 

Out of stock

SKU: 22101 - Category:

Description

An internal standard for the quantification of erlotinib by GC- or LC-MS,


Formal name: N-(3-ethynylphenyl)-6,7-bis[2-(methoxy-d3)ethoxy]-4-quinazolinamine, monohydrochloride

Synonyms: 

Molecular weight: 435.9

CAS: 1189953-78-3

Purity: ≥99% deuterated forms (d1-d6)

Formulation: A solid


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Kinase Inhibitors|CDKs||Product Type|Biochemicals|Kinase Inhibitors|EGFR/ErbB/HER Family||Product Type|Biochemicals|Kinase Inhibitors|JAK Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Signaling|Growth Factor Receptor Signaling||Research Area|Cancer|Cell Signaling|JAK/STAT Signaling